Stifel Financial Corp decreased its holdings in GlaxoSmithKline PLC (NYSE:GSK) by 6.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 917,957 shares of the pharmaceutical company’s stock after selling 58,431 shares during the period. Stifel Financial Corp’s holdings in GlaxoSmithKline PLC were worth $39,555,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. FMR LLC raised its holdings in GlaxoSmithKline PLC by 5.9% in the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock valued at $1,079,047,000 after buying an additional 1,389,238 shares during the period. Fisher Asset Management LLC raised its holdings in GlaxoSmithKline PLC by 4.7% in the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock valued at $540,483,000 after buying an additional 564,519 shares during the period. Renaissance Technologies LLC raised its holdings in GlaxoSmithKline PLC by 112.1% in the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after buying an additional 4,935,900 shares during the period. Hotchkis & Wiley Capital Management LLC raised its holdings in GlaxoSmithKline PLC by 4.3% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock valued at $338,377,000 after buying an additional 322,700 shares during the period. Finally, Bank of America Corp DE raised its holdings in GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock valued at $288,780,000 after buying an additional 934,928 shares during the period. Hedge funds and other institutional investors own 9.28% of the company’s stock.

GlaxoSmithKline PLC (GSK) traded up 0.4291% during mid-day trading on Thursday, hitting $40.5633. 730,927 shares of the stock were exchanged. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $44.54. The company has a 50-day moving average price of $39.76 and a 200-day moving average price of $41.75. The company has a market cap of $99.14 billion, a P/E ratio of 39.3055 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last posted its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The firm had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. On average, analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a $0.491 dividend. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a yield of 4.86%. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s payout ratio is 197.00%.

GSK has been the topic of several research reports. Morgan Stanley lowered shares of GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a report on Friday, September 8th. Argus restated a “buy” rating and issued a $50.00 price target on shares of GlaxoSmithKline PLC in a report on Thursday, August 31st. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a report on Tuesday, July 18th. ValuEngine lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BidaskClub upgraded shares of GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $44.67.

TRADEMARK VIOLATION WARNING: “Stifel Financial Corp Cuts Position in GlaxoSmithKline PLC (GSK)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/28/stifel-financial-corp-cuts-position-in-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.